Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
New Brunswick
New Jersey
08933
United States
Tel: 732-524-0400
Fax: 732-524-3300
Website: http://www.jnj.com/
2005 articles with Johnson & Johnson Family of Companies
-
Magnolia Neurosciences Corporation, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.
-
Johnson & Johnson Announces Chris DelOrefice as Vice President of Investor Relations
8/8/2018
Johnson & Johnson announced today the appointment of Chris DelOrefice to Vice President of Investor Relations for Johnson & Johnson, effective August 13, 2018.
-
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen
8/8/2018
The applications seek to update the Prescribing Information and Summary of Product Characteristics to provide health care professionals with the option to split the first infusion of DARZALEX® over two consecutive days.
-
Johnson & Johnson to Participate in the 2018 Wells Fargo 13th Annual Healthcare Conference
8/7/2018
Johnson & Johnson will participate in the 2018 Wells Fargo 13th Annual Healthcare Conference on Thursday, Sept. 6th, at The Westin Boston Waterfront in Boston, MA.
-
Allergan is suing Pfizer over a morphine-based opioid, Kadian, that Allergan acquired in December 2008.
-
IGM Biosciences, a privately-held biotech company located in Mountain View, California, announced that Daniel S. Chen will be the company’s new chief medical officer. Chen arrives from Genentech/Roche, where he was most recently vice president, Global Head of Cancer Immunotherapy.
-
Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical, indicated their guadecitabine (SGI-110) missed its co-primary endpoints in acute myeloid leukemia (AML).
-
First Ischemic Stroke Patients Treated With EMBOTRAP II Revascularization Device Since Commercial Availability In U.S.
7/24/2018
CERENOVUS Launches Next Generation Stent Retriever at Society of NeuroInterventional Surgery (SNIS) Annual Meeting
-
Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA™ (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation Scenario
7/24/2018
Phase 3 EMERALD and DIAMOND studies at AIDS 2018 reinforce the safety and efficacy of the first darunavir-based HIV-1 single-tablet regimen
-
Titan Spine Appoints Peter Wehrly to Board of Directors
7/23/2018
Highly Respected Industry Veteran to Provide Expertise and Counsel.
-
Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access
7/23/2018
Gamida Cell today announced the appointments of Tzvi Palash as chief operating officer (COO) and John D. Schick as vice president, market access.
-
Panther Medical Canada Inc. Opens in Canada Bringing State of the Art, Clinically Proven, Economically Viable Laparoscopic Surgical Solutions, while Saving Tax Payers Millions in Health Care Costs
7/18/2018
The use of staples over sutures reduces local inflammatory response, width of the wound, and the time it takes to close.
-
Johnson & Johnson Innovation Announces JPOD @ Philadelphia to Accelerate Healthcare Innovation in Philadelphia's Ecosystem
7/18/2018
JLABS will also launch a QuickFire Challenge to nurture local innovation
-
HIV patients have some good news this morning. The U.S. Food and Drug Administration approved Janssen Pharmaceutical’s Symtuza, the first and only complete darunavir-based single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1).
-
Johnson & Johnson Reports 2018 Second-Quarter Results
7/17/2018
2018 Second-Quarter Sales of $20.8 Billion Increased 10.6% versus 2017
-
The good news keeps coming for Janssen Pharmaceuticals’ SGLT2 diabetes drug Invokana. Late Monday the company said it was halting its Phase III chronic kidney disease trial early due to the fact that the drug had already achieved pre-specified efficacy data.
-
Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavi...
7/17/2018
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S FDA has approved SYMTUZA™, the first and only complete, darunavir-based single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically sup... -
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2018
7/16/2018
Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the third quarter of 2018 of $0.90 per share on the company's common stock.
-
Johnson & Johnson's Official Statement in Response to Today's Verdict in St. Louis Trial
7/13/2018
Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today's verdict in the St. Louis court.
-
In a particularly large result, a St. Louis jury awarded almost $4.7 billion in total damages to 22 women and their families in a lawsuit against Johnson & Johnson.